证券代码：301665 证券简称：泰禾股份 公告编号：2025-064 南通泰禾化工股份有限公司 关于增加埃及农药及功能化学品项目投资额度 暨对外投资进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 为充分把握市场机遇、优化项目一体化布局并提升公司的长期竞争力与经 济效益，经公司审慎研究，拟将该项目的总投资额由原不超过1.5亿美元增加至 不超过2.71亿美元（按照1美元兑换人民币7.1168元汇率折算约为19.29亿元）。 2025年11月20日公司召开第四届董事会第四次会议，审议通过了《关于对 外投资暨增加埃及农药及功能化学品项目投资额度的议案》。根据《深圳证券 交易所创业板股票上市规则》以及《深圳证券交易所上市公司自律监管指引第2 号——创业板上市公司规范运作》及相关法律法规的规定，本次事项在公司董 事会审议通过后，尚需提交股东会审议。本次增加埃及农药及功能化学品项目 投资额度暨对外投资进展的事项不构成关联交易，也不构成《上市公司重大资 产重组管理办法》规定的重大资产重组。 2、增加投资额度的原因 本次增加投资额度，是基于公司的审慎决策，旨在全方 ...

证券代码：301665 证券简称：泰禾股份 公告编号：2025-065 南通泰禾化工股份有限公司 关于召开 2025 年第三次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2025 年第三次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易 所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—创 业板上市公司规范运作》等法律、行政法规、部门规章、规范性文件及《公司 章程》的有关规定。 4、会议时间： 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日：2025 年 12 月 03 日 7、出席对象： （1）截至股权登记日 2025 年 12 月 03 日下午收市时在中国证券登记结算 有限责任公司深圳分公司登记在册的本公司全体已发行有表决权股份的股东均 有权出席股东会，并可以以书面形式委托代理人出席会议和参加表决，该股东 代理人不必是本公司股东。 （2）公司董事和高级管理人员； （3）公司聘请的见证律师； （4） ...

证券代码：301665 证券简称：泰禾股份 公告编号：2025-063 南通泰禾化工股份有限公司 第四届董事会第四次会议决议公告 本次会议以记名方式投票表决，逐项审议以下议案： 1、审议通过《关于增加埃及农药及功能化学品项目投资额度暨对外投资 进展的议案》 经审议，公司董事会同意增加埃及农药及功能化学品项目的投资金额，投 资金额由不超过 1.5 亿美元增至不超过 2.71 亿美元，资金来源包括自有及自筹 资金。 该事项已经第四届董事会战略委员会 2025 年第二次会议审议通过。 表决情况：同意 9 票，反对 0 票，弃权 0 票。 具体内容详见公司同日于中国证监会指定的信息披露网站巨潮资讯网 (www.cninfo.com.cn)披露的《关于增加埃及农药及功能化学品项目投资额度暨 对外投资进展的公告》。 本议案尚需提交公司 2025 年第三次临时股东会审议。 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 南通泰禾化工股份有限公司（以下简称"公司"）第四届董事会第四次会 议于 2025 年 11 月 20 日在公司会议室以现场和通讯相结 ...

Group 1 - The core products of the company, including Bacillus thuringiensis, 2,4-D, and pyraclostrobin, are experiencing sustained supply-demand tension in the market [1] - In the third quarter, the price of Bacillus thuringiensis remained at a high level, and the sales volume and profit of products increased due to concentrated shipments and the impact of order delivery schedules [1] - The demand for the company's core products is driven by the promotion of genetically modified crop planting and the significant expansion of planting areas in South America [1] Group 2 - The company's third-quarter report indicates that it achieved an operating income of 1.477 billion yuan, representing a year-on-year increase of 38.89% [1] - The net profit attributable to the parent company for the third quarter was 185 million yuan, reflecting a year-on-year growth of 204.65% [1] - Factors such as rolling order deliveries, channel stocking behaviors, and market psychology of "buying on the rise and not on the fall" have further amplified demand support [1]

Group 1 - The core viewpoint of the article is that Taihe Co., Ltd. (SZ 301665) has announced its participation in a research meeting with Invesco Great Wall Fund, where company executives addressed investor inquiries [1] - For the fiscal year 2024, Taihe Co., Ltd.'s revenue composition is as follows: pesticides account for 85.02%, functional chemicals for 11.2%, and others for 3.78% [1] - As of the report, Taihe Co., Ltd. has a market capitalization of 14 billion yuan [1]

Group 1: Performance Drivers - The core products such as Bacillus thuringiensis, 2,4-D, and Pyraclostrobin are experiencing sustained market supply and demand tension, with Bacillus thuringiensis prices at a temporary high in Q3 [2] - The sales volume and profit of these products increased due to concentrated shipments and order delivery schedules in Q3 [2] Group 2: Market Analysis - The demand for core products is boosted by the promotion of genetically modified crops and the significant expansion of planting areas in South America [2] - Consumer psychology of "buying high, not low" and behaviors like rolling order deliveries and channel stocking further support demand [2] Group 3: New Projects and Innovations - The price of Pyraclostrobin has slightly increased and remains stable, with no pressure on current capacity utilization [3] - The company is focusing on new materials and advancing high-contribution business directions, particularly in MX series products and downstream fluorinated materials [3] - The newly created pesticide, Cyhalofop-butyl, has launched under the "Bai Shi Jia" brand and has obtained domestic registration, with overseas registration in progress [3] Group 4: Competitive Advantages and Efficiency - Core products like Bacillus thuringiensis and 2,4-D are classified as restricted products in China, preventing new capacity approvals [3] - The company is enhancing capacity utilization through automation and process optimization, reducing energy consumption and labor costs while minimizing waste emissions [3] Group 5: Talent Development and Incentives - The company is building a "professional and composite" talent team across multiple business sectors and plans to attract high-end talent through long-term incentives [3] - The incentive plan is currently under adjustment, with no specific timeline for implementation [3] Group 6: Risk Considerations - The information shared in this survey does not constitute a substantive commitment to investors regarding external environment judgments, company development strategies, or future plans [3]

资料显示，南通泰禾化工股份有限公司位于上海市长宁区临虹路365号北5座，成立日期2004年4月29 日，上市日期2025年4月11日，公司主营业务涉及农药产品以及功能化学品的研发、生产和销售。主营 业务收入构成为：除草剂43.14%，杀菌剂37.30%，功能化学品9.98%，其他9.57%。 截至11月10日，泰禾股份股东户数1.28万，较上期增加3.62%；人均流通股2989股，较上期减少3.49%。 2025年1月-9月，泰禾股份实现营业收入38.90亿元；归母净利润3.67亿元，同比增长120.56%。 11月17日，泰禾股份涨1.34%，成交额2.12亿元。两融数据显示，当日泰禾股份获融资买入额1835.27万 元，融资偿还2650.61万元，融资净买入-815.34万元。截至11月17日，泰禾股份融资融券余额合计 8504.12万元。 融资方面，泰禾股份当日融资买入1835.27万元。当前融资余额8504.12万元，占流通市值的6.99%。 融券方面，泰禾股份11月17日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股，融券余额0.00元。 分红方面 ...

证券日报网讯泰禾股份（301665）11月17日在互动平台回答投资者提问时表示，截至2025年11月10日， 公司股东总户数为12，794户。 ...

格隆汇11月17日丨泰禾股份(301665.SZ)在互动平台表示，公司暂未涉及lifsi产品。 ...

Core Points - On November 12, Taihe Co., Ltd. experienced a decline of 1.65% in stock price, with a trading volume of 91.42 million yuan [1] - The financing data for Taihe on the same day showed a financing purchase amount of 8.13 million yuan and a financing repayment of 8.92 million yuan, resulting in a net financing outflow of 0.79 million yuan [1] - As of November 12, the total margin balance for Taihe was 85.12 million yuan, accounting for 7.20% of its market capitalization [1] Financing and Margin Data - The financing purchase on November 12 was 8.13 million yuan, while the current financing balance stands at 85.12 million yuan [1] - No shares were sold or repaid in the securities lending segment on November 12, with a total of 0 shares and 0 yuan in margin balance [1] Company Overview - Taihe Co., Ltd. is located in Changning District, Shanghai, and was established on April 29, 2004, with its listing date set for April 11, 2025 [1] - The company specializes in the research, production, and sales of pesticide products and functional chemicals, with revenue composition as follows: herbicides 43.14%, fungicides 37.30%, functional chemicals 9.98%, and others 9.57% [1] Financial Performance - For the period from January to September 2025, Taihe reported a revenue of 3.89 billion yuan and a net profit attributable to shareholders of 367 million yuan, reflecting a year-on-year growth of 120.56% [1] Shareholder Information - As of November 10, the number of shareholders for Taihe was 12,800, an increase of 3.62% from the previous period, with an average of 2,989 circulating shares per person, a decrease of 3.49% [1] - Since its A-share listing, Taihe has distributed a total of 270 million yuan in dividends [2] - As of September 30, 2025, Hong Kong Central Clearing Limited was the sixth largest circulating shareholder, holding 230,200 shares, a decrease of 171,700 shares from the previous period [2]